Generic drug approvals during GATT transitional period would be allowed by Sen. Pryor's S 1191.
GENERIC FIRMS COMPLETING "PENULTIMATE STEPS" OF ANDA PROCESS prior to June 8, 1995 would be permitted to market a product during the patent extension resulting from the 20-years-from-filing system adopted in the Uruguay Round Agreements Act under legislation introduced by Sen. Pryor (D-Ark.) Aug. 11. The "Consumer Access to Prescription Drugs Act" (S 1191) defines the "substantial investment" that would allow marketing during the URAA transitional period as: "the development of a product formulation and the manufacture of an experimental batch of a drug that becomes the subject of an application, or the initiation of stability or bioequivalency studies by an applicant."
You may also be interested in...
The 2002 Maine senatorial campaign features a race between an author of the Senate's generic drug reform bill and a sponsor of legislation creating the "Maine Rx" state drug assistance program
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011